137 related articles for article (PubMed ID: 37113049)
1. Impact of initiating oral anticancer agents for leukemia on adherence to medications for multiple chronic conditions.
Gatwood J; Dashputre A; Rajpurohit A; Gatwood K; Mackler E; Wallace L; Farris K; Rizvi-Toner A; Farley J
J Oncol Pharm Pract; 2024 Mar; 30(2):342-353. PubMed ID: 37113049
[TBL] [Abstract][Full Text] [Related]
2. Medication Adherence Among Adults With Comorbid Chronic Conditions Initiating Oral Anticancer Agent Therapy for Multiple Myeloma.
Gatwood J; Dashputre A; Rajpurohit A; Gatwood K; Mackler E; Wallace L; Farris K; Rizvi-Toner A; Farley J
JCO Oncol Pract; 2022 Sep; 18(9):e1475-e1483. PubMed ID: 35700416
[TBL] [Abstract][Full Text] [Related]
3. Medication Adherence, Health Care Utilization, and Costs Among Patients Initiating Oral Oncolytics for Multiple Myeloma or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Dashputre AA; Gatwood KS; Gatwood J
J Manag Care Spec Pharm; 2020 Feb; 26(2):186-196. PubMed ID: 32011965
[TBL] [Abstract][Full Text] [Related]
4. Impact of oral oncolytic initiation on medication adherence for pre-existing comorbid chronic conditions.
Dashputre AA; S Gatwood K; Schmidt J; Gatwood J
J Oncol Pharm Pract; 2020 Jun; 26(4):835-845. PubMed ID: 31575355
[TBL] [Abstract][Full Text] [Related]
5. Treatment utilization patterns of newly initiated oral anticancer agents in a national sample of Medicare beneficiaries.
Doshi JA; Jahnke J; Raman S; Puckett JT; Brown VT; Ward MA; Li P; Manz CR
J Manag Care Spec Pharm; 2021 Oct; 27(10):1457-1468. PubMed ID: 34595957
[No Abstract] [Full Text] [Related]
6. Implementation of a model integrating primary and oncology pharmacists' care for patients taking oral anticancer agents (OAA).
Farris KB; Cadwallader T; Farley J; Gatwood K; Mackler E; Gatwood J
Explor Res Clin Soc Pharm; 2022 Sep; 7():100163. PubMed ID: 35957656
[TBL] [Abstract][Full Text] [Related]
7. Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.
Winn AN; Keating NL; Dusetzina SB
J Clin Oncol; 2016 Dec; 34(36):4323-4328. PubMed ID: 27998234
[TBL] [Abstract][Full Text] [Related]
8. The effects of oral anticancer parity laws on out-of-pocket spending and adherence among commercially insured patients with chronic myeloid leukemia.
Spargo A; Yost C; Squires P; Raju A; Schroader B; Brown JD
J Manag Care Spec Pharm; 2021 May; 27(5):554-564. PubMed ID: 33908275
[No Abstract] [Full Text] [Related]
9. Oral Anticancer Agent (OAA) Adherence and Survival in Elderly Patients With Metastatic Renal Cell Carcinoma (mRCC).
Dinan MA; Wilson LE; Greiner MA; Spees LP; Pritchard JE; Zhang T; Kaye D; George D; Scales CD; Baggett CD; Gross CP; Leapman MS; Wheeler SB
Urology; 2022 Oct; 168():129-136. PubMed ID: 35878815
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine Kinase Inhibitors and the Relationship With Adherence, Costs, and Health Care Utilization in Commercially Insured Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
Phuar HL; Begley CE; Chan W; Krause TM
Am J Clin Oncol; 2020 Jul; 43(7):517-525. PubMed ID: 32304434
[TBL] [Abstract][Full Text] [Related]
11. Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs.
Ward MA; Fang G; Richards KL; Walko CM; Earnshaw SR; Happe LE; Blalock SJ
Curr Med Res Opin; 2015 Feb; 31(2):289-97. PubMed ID: 25420131
[TBL] [Abstract][Full Text] [Related]
12. Initiation of generic imatinib may improve medication adherence for patients with chronic myeloid leukemia.
Cole AL; Jazowski SA; Dusetzina SB
Pharmacoepidemiol Drug Saf; 2019 Nov; 28(11):1529-1533. PubMed ID: 31507005
[TBL] [Abstract][Full Text] [Related]
13. Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment.
Trivedi D; Landsman-Blumberg P; Darkow T; Smith D; McMorrow D; Mullins CD
J Manag Care Spec Pharm; 2014 Oct; 20(10):1006-15. PubMed ID: 25278323
[TBL] [Abstract][Full Text] [Related]
14. Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.
Guérin A; Chen L; Dea K; Wu EQ; Goldberg SL
Curr Med Res Opin; 2014 Jul; 30(7):1345-52. PubMed ID: 24640967
[TBL] [Abstract][Full Text] [Related]
15. Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinoma.
Kaye DR; Wilson LE; Greiner MA; Spees LP; Pritchard JE; Zhang T; Pollack CE; George D; Scales CD; Baggett CD; Gross CP; Leapman MS; Wheeler SB; Dinan MA
J Geriatr Oncol; 2022 Jun; 13(5):614-623. PubMed ID: 35125336
[TBL] [Abstract][Full Text] [Related]
16. Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma.
Spees LP; Wheeler SB; Jackson BE; Baggett CD; Wilson LE; Greiner MA; Kaye DR; Zhang T; George D; Scales CD; Pritchard JE; Leapman M; Gross CP; Dinan MA
Cancer Med; 2021 Oct; 10(19):6653-6665. PubMed ID: 34480518
[TBL] [Abstract][Full Text] [Related]
17. [A case of chronic myeloid leukemia occurring during treatment for chronic lymphocytic leukemia].
Hattori H; Kuwayama M; Kotake T; Karasuno T
Gan To Kagaku Ryoho; 2011 Feb; 38(2):333-6. PubMed ID: 21368508
[TBL] [Abstract][Full Text] [Related]
18. Chronic Myelogenous Leukemia Diagnosed in the Setting of Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Viswanathan K; Roboz G; Chadburn A; Mathew S
Int J Surg Pathol; 2020 Apr; 28(2):216-224. PubMed ID: 31544558
[TBL] [Abstract][Full Text] [Related]
19. Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia.
Lam MS; Cheung N
J Oncol Pharm Pract; 2016 Dec; 22(6):741-748. PubMed ID: 26419691
[TBL] [Abstract][Full Text] [Related]
20. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia.
Wu EQ; Guerin A; Yu AP; Bollu VK; Guo A; Griffin JD
Curr Med Res Opin; 2010 Dec; 26(12):2861-9. PubMed ID: 21062136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
